Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | VNN1 | O95497 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10285108 | 0.85 | KDM4E (0.51) | KMT2AVNN1CYP2C9CYP2C19KDM4E | |
| SCHEMBL19332795 | 0.85 | KMT2A (0.49) | KMT2AVNN1KDM4ETSHRALDH1A1 | |
| SCHEMBL20510206 | 0.85 | KMT2A (0.49) | KMT2AVNN1KDM4ETSHRALDH1A1 | |
| SCHEMBL19332796 | 0.85 | KMT2A (0.49) | KMT2AVNN1KDM4ETSHRALDH1A1 | |
| SCHEMBL23852059 | 0.83 | MAPT (0.49) | KMT2AKDM4ETSHRALDH1A1NAMPT | |
| SCHEMBL31153568 | 0.80 | KDM4E (0.49) | KMT2ACYP2C9KDM4ETSHRNAMPT | |
| SCHEMBL25649379 | 0.79 | PARP1 (0.43) | KMT2AKDM4ETSHRPARP1 | |
| SCHEMBL10250905 | 0.77 | KDM4E (0.48) | KMT2ACYP2C9CYP2C19KDM4ETSHR | |
| SCHEMBL29542522 | 0.76 | CDK9 (0.46) | KMT2AKDM4ETSHR | |
| SCHEMBL19352961 | 0.76 | GRIN2B (0.55) | KMT2ACYP2C9ALDH1A1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210107903-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | Suzhou Baijibugong Pharmaceutical Technology Co., Ltd. (CN) | 2021-04-15 | — | — | US | disclosed |
| US-10870652-B2 | Compounds and methods for modulating bruton's tyrosine kinase | CORVUS PHARMACEUTICALS, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-20190106423-A1 | COMPOUNDS AND METHODS FOR MODULATING BRUTON'S TYROSINE KINASE | CORVUS BIOPHARMACEUTICALS, LTD. (KY) | 2019-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106423-A1 | COMPOUNDS AND METHODS FOR MODULATING BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | KMT2A 1371/4885VNN1 4129/4885CYP1A2 4585/4885 |
| US-20210107903-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | KMT2A 1577/4885VNN1 4453/4885CYP1A2 2289/4885 |
| US-10870652-B2 | Compounds and methods for modulating bruton's tyrosine kinase | ABL1, BTK, LYN | KMT2A 1371/4885VNN1 4129/4885CYP1A2 4585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.